FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Dunne Michael W.					2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]										onship of Reporting Person(s) to Il applicable) Director			o Issuer 10% Owner	
(Last)	(First)	,	liddle)			3. Date of Earliest Transaction (Month/Day/Year) 12/23/2022								Officer (g below)	ive title		Other (s below)	pecify	
C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) DUBLIN 2	L2	(7													Form filed	d by More	than C	ne Reportin	g Person
(City)	(State)	`	able I - Nor	n-Deri	ivativ	e Se	curitie	s Aco	uired I	Disn	osed of	f or Rene	ficia	ally Ow	ned				
Date					nth/Day/Year)		2A. Deem Executior if any (Month/Da	n Date,	Code (Insti		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			5. Amount Securities Beneficially Following I Transaction (Instr. 3 and	y Owned Reported (Instruction)		lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	te, Tr	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Destricted Cher-				C	ode	v	(A)	(D)	Date Exercisat		Expiration Date	Title	or Nu	mount umber Shares		(Instr. 4)	ion(s)		
Restricted Share Units	(1)	12/23/2022			A		3,487		(2)		(2)	Ordinary Shares] :	3,487	\$0.00	3,487	7	D	

Explanation of Responses:

- 1. Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.
- 2. Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023.

Remarks:

/s/ Michael W. Dunne

** Signature of Reporting Person

12/28/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.